Introduction
Prostate cancer (PCa) is the second most lethal cancer among men in the U.S. with 26,730 estimated deaths in 2017 [1] . To address this problem, significant advances have been made in diagnostic imaging, which have aimed to characterize primary prostatic lesions, correlate with the clinical state of disease, and monitor response to therapy [2] . The current standard-of-care imaging, however, cannot adequately monitor the spread of disease from the primary site to regional lymph nodes and distant metastatic sites or annotate the genomic evolution of disease during this process. As the detection of metastatic lesions and spread is crucial for the staging, management, and disease-specific survival of PCa, an imaging biomarker-based solution appears necessary.
Prostate-specific membrane antigen (PSMA) is a candidate antigen on which to target a biomarker-based strategy. It is an extracellular glutamate carboxypeptidase II and a zinc metalloenzyme that catalyzes the hydrolysis of Cterminal glutamate in peptides. More importantly, it is highly expressed in both primary and metastatic PCa lesions, correlating with the stage/grade of the PCa [3] . PSMA was originally detected in the androgen-dependent PCa cell line LNCaP and was thought to be confined to prostate tumors, but subsequent studies have revealed that PSMA is expressed in the neovasculature of many other tumors [4] . Regardless, this relative selectivity still makes PSMA a very attractive target for developing targeted imaging and therapeutic agents. Accordingly, several biological vectors including antibodies [5] , peptides [6] , small molecules, and particles have been developed and evaluated as potential carriers for imaging and therapeutic entities.
Urea-glutamate-based small molecule antagonist probes have recently gained favor among other alternatives, as their molecular weight, ease of labeling, fast clearance, and ability to label with short-lived isotopes (e.g., Ga-68 and F-18) permit repetitive imaging. A variety of positron emission tomography (PET)/single photon emission computed tomography probes using I-123, Ga-68, and F-18 have been developed and evaluated in both preclinical and clinical settings [7] [8] [9] [10] [11] [12] . Recently, [
68 Ga]DKFZ11-PSMA developed by Eder and colleagues [13] has gained significant popularity due to its ease of labeling and superior performance in vivo in detecting both primary and metastatic PCa lesions. The tracer demonstrated 100 % sensitivity and specificity in a cohort study of 319 patients [14] . While many studies have focused on optimizing the radiosynthesis and findings on the ability to detect lesions in patient populations using [
68 Ga]DP11 have been published, so far, none of the studies have addressed the question of reproducibility of scans. For a receptor-targeted radiopharmaceutical, residual activity can impact the subsequent scan. This is important if PSMA-based imaging is being used for measuring response to therapy on a routine basis [17] . This is also important for PSMA-targeted therapeutic approaches that leverage these urea-glutamate-based small molecules for delivering toxins or therapeutic radionuclides [18] , as receptor availability is one of the critical limiting factors. In the current manuscript, we have addressed using PSMAexpressing PC3-PIP xenografts, specifically whether imaging these tumors with [
68 Ga]DP11 affects subsequent serial scans performed at 24 and 48 h.
Materials and Methods
All starting materials, solvents, and reagents were purchased from commercial sources (Sigma-Aldrich, St. Louis, MO and Thermo Fisher Scientific, Waltham, MA) and used without further purification. The radiochemical precursor DFKZ-PSMA11 (catalog number 9920.0001) was purchased from ABX (Radeberg, Germany) and dissolved in chelexed water to achieve a concentration of 1 mg/ml, and 10 μg (10 μl) was aliquoted in 1.5-ml microcentrifuge tubes and stored at −20°C and used for reactions. All solvents used for high-performance liquid chromatography (HPLC) analysis and purification were purchased from Fisher Scientific (HPLC grade). For radiosynthesis, TraceSELECT® or TraceSELECT® Ultra (Sigma-Aldrich) grade reagents were used. The reagents included KOH, acetic acid, 30 % HCl, KCl, and CH 3 CN. Water (918.2 MΩ cm −1 at 25°C) was obtained from an Alpha-Q Ultrapure water system (Millipore, Bedford, MA). C-18 reversed phase cartridge Strata™-X (#8B-S100-TAK, 33 μm polymeric reversed phase C-18, 30 mg/1 ml) and HPLC column Luna (00G-4252-E0, 250 × 4.6 mm, 5 m, 100 Å, C-18 with TMS endcapping) were purchased from Phenomenex (Torrance, CA).
Cell Lines
PC-3 cell lines were obtained from the American Type Culture Collection (Manassas, VA) and cultured in F12-K medium with 10 % FCS, 2 mM L-glutamine, 1.5 g/l sodium bicarbonate, and penicillin-streptomycin. PC3-PIP cells were kindly provided by Dr. Martin Pomper (Johns Hopkins University, Baltimore, MD) and maintained under RPMI 1640 medium with 10 %FCS and penicillin-streptomycin.
Radiosynthesis
Gallium-68 was eluted from the ANSTO generator using 0.3 N HCl, trapped on a cation exchange column (Biorad 4 ] using 0.5-M KOH solution in 600-μl volume [19] .To neutralize and acidify the solution, 26 μl of glacial acetic acid (93 μL per 100 μl of 0.5 M KOH) was added to 500-μl eluate. The pH was G5 (pH paper) and about 50 μl of NaOAc buffer (2 mM, pH 4.2) was added. [
68 Ga]DP11 was synthesized by adding 20 μg of DKFZ-PSMA11 ligand (947 MW, 21.1 nmol) to a 600-μl solution of [
68 Ga]Ga(OAc) 3 (~555 MBq/15 mCi) in NaOAc (0.5 M, pH 4.5) buffer and incubating the reaction mixture for 10 min at 37°C (Fig. 1) . The compound was purified by passing through a Strata™-X cartridge (#8B-S100-TAK, 33 μm polymeric reversed phase C-18, 30 mg/ 1 ml) preconditioned with 1 ml of 95 % ethanol and 2.5 ml of pure water. The cartridge was then rinsed with 3 ml of water to remove any residual free Ga-68, and finally, the purified Ga-68 peptide conjugate was eluted in 500 μl of ethanol (95 % in saline). The purity of the compound was analyzed using HPLC on a C18 column (Phenomenex Luna, 250 × 4.6 mm, 5 m, 110 Å) using a solvent of 22 % CH 3 CN in 0.1 % trifluoroacetic acid solution in the water. The product was concentrated under reduced pressure to reduce ethanol content and formulated in 0.9 % saline.
For the synthesis of [ 67 Ga]DP11, [ 67 Ga]GaCl 3 (74 MBq/ 2 mCi) in 0.1 N HCl was added to an Eppendorf tube containing 30 μg of DKFZ-PSMA11 (947 MW, 31.6 nmol) and allowed to react at 37°C for 120 min. HPLC analysis (using the conditions described above) was performed to ensure complete complexation of gallium and the product was diluted using PBS and used without any further purification.
Xenografts
All animal experiments were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee of Memorial Sloan Kettering Cancer Center and followed National Institutes of Health guidelines for animal welfare. Bilateral tumor subcutaneous xenografts of PC3-PIP (PSMA+) and PC3 (PSMA−) were established for imaging and biodistribution studies. Slow-growing PC3 tumors xenografts were first established by administration of 5 × 10 6 cells in 200 μl (1:1 F12-K medium and Matrigel®) on the left flank under 2 % isoflurane anesthesia and allowed to reach a volume of 150 mm 3 , which needed approximately 6-10 days. This was followed by inoculation of fast-growing PC3-PIP tumor cells (5 × 10 6 cells in 20 μl in 1:1 RPMI-1640 and Matrigel®) on the right flank of the mice under 2 % isoflurane anesthesia. By days 30-35, the tumors were ready for imaging and biodistribution studies.
Small Animal PET Imaging
Small animal PET imaging studies were performed on a dedicated small animal PET scanner (Focus 120 microPET; Siemens Medical Solutions USA, Inc.). Mice were maintained under 2 % isoflurane anesthesia in oxygen at 2 l/min during the entire scanning period. Athymic nude mice bearing PC3-PIP (PSMA+) and PC3 (PSMA−) bilateral tumor xenografts were used for imaging and biodistribution studies. For the repeatability study, group 1 (Fig. 1) 
67 Ga]DP11 per injection. An energy window of 350-700 keV and a coincidence timing window of 6 ns were used. The imaging data were corrected for non-uniformity of the scanner response, dead time count losses, and physical decay to the time of injection, but not for attenuation, scatter, or partial volume averaging. The spatial resolution of the Focus 120 scanner at the center of the field of view is~1.6 mm full width at half maximum. The count rates in the reconstructed images were converted to percentage injected dose per gram of tissue (%ID/g) using a calibration factor (0.037 MBq/ml/cps/voxel) derived by imaging a mouse-size water-equivalent phantomcontaining Ga-68.
Group 1 mice also received [ 67 Ga]-DP11 on day 2 and were sacrificed on day 3, 60 min post-administration, and all the organs were collected. To ensure reproducibility of the imaging studies, we administered the same amount (~5.5 MBq/150 μCi) of [
68 Ga]DP11 with SA of about 22.9 GBq/μmol (620 mCi/μmol). For measuring intra-day variability, group 3 mice were imaged with [
67 Ga]DP11 in the morning and underwent repeated imaging with 7.4 MBq (200 μCi) [
68 Ga]DP11 at 7 h after the first injection. Region of interest (ROI) image analysis was performed using ASIPro VM® software, which was provided by the vendor. A total of 18-20 2D ROIs were drawn around the tumor using the free trace setting across the coronal plane. The activity, volume, and %ID/cm 3 details generated by the software on these slices were used for data analysis.
Biodistribution Studies
For terminal biodistribution studies, mice with PC3 and PC3-PIP bilateral tumors were injected with~5. The exact dose delivered to each animal was determined by measuring radioactivity in the syringe before and after administration in an energy-calibrated dose calibrator (CRC-15R) The animals were euthanized at different time points, organs harvested, and radioactivity measured in a calibrated γ-counter (1480 Wizard 3 Auto γ-counter) using a 400 to 600-keV energy 
PET Imaging Study
Small animal PET imaging was performed on mice bearing PC3-PIP (R) and PC3 (L) bilateral tumors to evaluate the repeatability of imaging with [ 68 Ga]DP11 on consecutive days. Fig. 2 shows representative coronal and transaxial slices of PET images obtained using the same mice for 3 consecutive days. As expected, only PSMA+ PC3-PIP tumors displayed uptake, whereas PC3 tumors had minimal or no uptake. Qualitatively, the images indicated that accumulation of the tracer in the tumors was virtually the same on the 3 consecutive days. Additionally, we observed that the kidneys have the highest uptake with rapid clearance from the rest of the organs.
To obtain quantitative information, ROI analysis of the imaging study in mice bearing PC3-PIP (R) tumors indicated that the uptake was constant during the imaging period of 3 consecutive days. PC3 tumors could not be visualized or delineated with the [ 68 Ga]DP11 tracer and therefore we could not perform ROI analysis, so only the biodistribution study was performed. Fig. 3 shows the performance of the [ 68 Ga]DP11 in PC3-PIP tumors on consecutive imaging days, demonstrating constant uptake. To minimize the influence of parameters of inter-tumor heterogeneity, size, body weight, etc. of the mice, we compared the relative uptake of the tracer in each mouse. Fig. 4 Ga]DP11 on the same day (group 3) indicate that the uptake in tumor is 13.82 ± 3.77 and 17.76 ± 1.84 in the morning and evening, respectively (Fig. 4) . Additionally, the uptake in other organs remains fairly constant in both the studies (Table 2) .
Discussion
Many emerging imaging modalities and agents designed to evaluate PCa metastatic lesions in the most appropriate clinical context are currently under evaluation. It is well understood that the current standard-of-care imaging agents are either non-quantitative or do not report information relevant to the clinical setting. Of the FDA-approved molecular imaging (PET) agents in the U.S., the currently approved radiopharmaceuticals ([ 1 1 C]choline and [ 18 F]FACBC) also have well-documented limitations regarding specificity and stage-specific information. Investigational PSMA small molecule antagonists have been used extensively outside the U.S. and in more limited research protocols in the U.S., but challenges remain in getting FDA approval and developing a biomarker-based imaging strategy for PCa. Conceptually, the success of a small antibody fragment phase I trial [20] at our institution is an intriguing prelude to the use of shorter-lived small molecule tracers, which addresses a persistent desire for a similar but costeffective alternative. 68 Ga]DP11 in small animals. This process involves several components, but almost all rely on the agent being dispensed from a single source to a hub of satellite imaging sites. To accomplish this task, the agent must be able to provide reliable quantitative information under a variety of conditions seen in complex trials of human subjects when the goal is viable information for both clinicians and regulatory authorities.
The biodistribution results demonstrate at least two important points. The first is that, as expected, the choice of gallium label did not affect the binding, internalization, or residualization of the antagonist in this context. This was an important point that allowed us to complete an inter-and intra-day repeat analysis with the knowledge that we were not perturbing the expression of the antigen on the cell surface. Secondly, the biodistribution of the Ga-68 on the same and subsequent days confirmed our hypothesis with the candidate radiotracer and allowed the proper context to look at the high and low SA values without the confound of altered expression levels or altered interaction with the radiotracer antagonist.
For an investigational imaging agent to succeed, numerous hurdles must be addressed as it is examined as a clinical trial agent. For [
68 Ga]DP11, its production at multiple sites could be a serious impediment with respect to both scientific and economic constraints. Here, we address the issue of SA and repeatability of uptake in a murine model.
Based on our study, we can also conclude that a patient on a PSMA-targeted diagnostic protocol can be administered the corresponding PSMA-targeting therapeutic agent (e.g., [ 177 Lu]DKFZ-PSMA617 or [
225 Ac]DKFZ-PSMA617) on the same day without adversely affecting the target of the 68 Ga]DP11 1 h post-administration in mice bearing PC3-PIP tumor xenografts that were imaged 7 h apart on the same day (group 3). 
